Genomic Health

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Retrieved on: 
金曜日, 4月 29, 2022
Oncotype (Denmark), Solution, Medicine, Breast cancer, The New England Journal of Medicine, ASCO, Exact Sciences (company), Electric Bond and Share Company v. Securities and Exchange Commission, DCIS, Patient, Colon, Risk, Genomic Health, American Society of Clinical Oncology, Neoplasm, Cancer, Lymph, Annual report, Biomarker, Woman, Exact sciences, News, Security (finance), Breast, Physician, Prostate cancer, NASDAQ, Recurrence, MAP, Society, Genomics, Biology, Medical device, Medical imaging, Facebook

Postmenopausal women with Oncotype DX Breast Recurrence Score results of 0 to 25 did not show benefit from the addition of chemotherapy to hormone therapy.

Key Points: 
  • Postmenopausal women with Oncotype DX Breast Recurrence Score results of 0 to 25 did not show benefit from the addition of chemotherapy to hormone therapy.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Recurrence Score and Oncotype MAP are trademarks or registered trademarks of Genomic Health, Inc.

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

Retrieved on: 
月曜日, 3月 7, 2022
People, Risk, Genomic Health, Exact sciences, Oncotype (Denmark), Social media, Ageing, American Cancer Society, Patient, Colorectal cancer, Research, Woman, Colonoscopy, Katie, DNA, National Colon Cancer Awareness Month, Inflammatory bowel disease, Medicare, Friends, Blood, FDA, Awareness, Solution, American Cancer Society Cancer Action Network, National Comprehensive Cancer Network, COVID-19, Cancer, Man, Time, Trial of the century, CEO, Hereditary nonpolyposis colorectal cancer, Adenoma, The New England Journal of Medicine, Katie Couric, Health, NASDAQ, Mobile phone, Dietary supplement, Health insurance, Facebook, Exact Sciences (company)

"All adults 45 years or older should be screened for colon cancer," said Kevin Conroy, chair and CEO of Exact Sciences.

Key Points: 
  • "All adults 45 years or older should be screened for colon cancer," said Kevin Conroy, chair and CEO of Exact Sciences.
  • "Together with Katie, we're working to help raise awareness about early detection and the availability of colon cancer screening options, including non-invasive at-home tests like Cologuard.
  • Since its launch in 2014, nearly 8 million people have used Cologuard to screen for colon cancer at home.
  • Launching today to coincide with Colorectal Cancer Awareness Month, 'Mission to Screen' will be placed in broadcast and digital outlets.

Allelica, the Leader in Polygenic Risk Scoring, Expands Scientific Advisory Board

Retrieved on: 
木曜日, 2月 3, 2022
People, CEO, Tufts University, View, Patient, Risk, Pathology, Institute, Department of Medicine – University of Pamplona, University, Heart failure, Policy, Icahn School of Medicine at Mount Sinai, Center, UCSF, Mount Sinai, MCRI, University of Pittsburgh Medical Center, Tufts University School of Medicine, Dilated cardiomyopathy, Pharmacology, Research, Genetic, PRS, Medicine, Partnership, Disease, Hospital, Look, Gene, Biomarker, Precision medicine, Genetic distance, Genome, Cardiovascular disease, PHD, Doctor of Philosophy, Merck, Algorithm, Department, Cardiology, Division, Internal medicine, MPH, Broad Institute, Harvard Medical School, Health information management, Foundation, Multimedia, Genetics, Brigham and Women's Hospital, Genomic Health, Solution, Pharmaceutical industry, Medical device, MD, Genomics

"We are delighted to welcome four leading scientists in their respective fields to help guide Allelica in our mission to advance disease prevention through broader application of polygenic risk scores in healthcare."

Key Points: 
  • "We are delighted to welcome four leading scientists in their respective fields to help guide Allelica in our mission to advance disease prevention through broader application of polygenic risk scores in healthcare."
  • She is an associate professor of medicine and genetics and board certified in internal medicine and medical genetics.
  • In addition to these US-based experts, Allelica's international Advisory Board includes PRS pioneer,Professor Bjarni Vilhjlmsson,from Denmark.
  • Allelica is a leading genomic software company specializing in secure and scalable solutions to implement clinical grade polygenic risk scores (PRSs).

Women's Health Diagnostics Market (2021 - 2026): Rapid Growth Expected Due to Rising Incidence of Chronic and Lifestyle Related Disorders - ResearchAndMarkets.com

Retrieved on: 
金曜日, 1月 28, 2022
General Health, Women, Consumer, Health, Oncology, People, Awareness, Diagnosis, Risk, Patient, EPIQ, Breast cancer, Oncology, Hospital, Insurance, European Society for Medical Oncology, ESMO, Organization, Radiation therapy, Genomic Health, Adoption, Ovarian cancer, Woman, Research, COVID-19, Transport, Workforce, CAGR, Cancer, Cervical cancer, Prevalence, Osteoarthritis, List of American Medical Association journals, Philips, Incidence, Travel, Academic Medicine (journal), Investment, Peaceful transition of power, Medical imaging, Vaccine, Birth control, Medical device, Growth

The women's health diagnostics market is expected to register a CAGR of 7.5% over the forecast period.

Key Points: 
  • The women's health diagnostics market is expected to register a CAGR of 7.5% over the forecast period.
  • The market will show rapid growth due to the rising incidence of chronic and lifestyle-related disorders, the rising number of imaging and diagnostic centers, and the increased adoption of point-of-care and rapid diagnostic tests.
  • The women's health diagnostics market is growing due to the increasing prevalence of osteoarthritis, ovarian cancer, breast cancer, and cervical cancer.
  • Additionally, the growth in breast cancer diagnostics reimbursement and insurance coverage is expected to drive vertical growth.

Global Cancer/Tumor Profiling Market (2021 to 2030) - Opportunity Analysis and Industry Forecasts - ResearchAndMarkets.com

Retrieved on: 
水曜日, 1月 19, 2022
Health, General Health, Biomarker, Research, Patient, Technology, Man, Lymphoma, Precision medicine, Prostate cancer, International Agency for Research on Cancer, Adoption, Population, Protein, Breast cancer, Gene, Organic, Disease, Acute leukemia, Genomic Health, Top, Computer Sciences Corporation, Prevalence, Lung cancer, Woman, Medical imaging, Pharmaceutical industry, Mobile phone, Cancer

Cancer profiling is not only effective in the molecular profiling of common malignancies like lymphoma and breast cancer, but also in the molecular profiling of lung cancer, prostate cancer, and acute leukaemia.

Key Points: 
  • Cancer profiling is not only effective in the molecular profiling of common malignancies like lymphoma and breast cancer, but also in the molecular profiling of lung cancer, prostate cancer, and acute leukaemia.
  • Market Share Analysis of Top Global Cancer Tumor Profiling Providers, 2020
    5.2.
  • Market Share Analysis of Top North America Cancer Tumor Profiling Providers, 2020
    5.5.
  • Market Share Analysis of Top Row Cancer Tumor Profiling Providers, 2020
    7.

InterVenn Biosciences Names Brian Hogan as Chief Financial Officer

Retrieved on: 
木曜日, 1月 6, 2022
Technology, Medical Devices, Hospitals, Clinical Trials, Nanotechnology, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Clear Labs, California State University, View, Liver, Lung, Growth, Therapy, HIV disease progression rates, Kidney, Cancer, Prostate, History, CEO, MBA, Biomarker, Genome, Accounting, Business administration, Glycolipid, Biology, CFO, Liquid biopsy, VP, Industry, Genomic Health, Leadership, Management, Pharmaceutical industry

InterVenn Biosciences, the leader in glycoproteomics, today announced that it has named Brian Hogan as Chief Financial Officer.

Key Points: 
  • InterVenn Biosciences, the leader in glycoproteomics, today announced that it has named Brian Hogan as Chief Financial Officer.
  • I am delighted to welcome Brian to InterVenn as our CFO, said Aldo Carrascoso, CEO of InterVenn.
  • Im excited to join InterVenn on its mission to positively impact peoples lives through its breakthrough innovation that targets life-threatening disease, said Brian Hogan, CFO of InterVenn.
  • Brian brings over 20 years of finance and leadership experience in public and private companies to InterVenn.

Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer

Retrieved on: 
月曜日, 12月 13, 2021
Research Triangle Park, US, Genomics, NGS, Neuropathology, Clinical trial, University, Doctor of Philosophy, Cancer Research UK, Triangle Park (Quezon City), Radar, Industry, Title 42 appointment, Biomarker, Cambridge Institute for Sustainability Leadership, D, Cancer research, NASDAQ, CMO, NeoGenomics, University of Cambridge, Research, MD, Biotechnology, Patient, Therapy, Leadership, Drug development, Certification, Liquid biopsy, Laboratory, VC, Recurrence, Genomic Health, American Board of Commissioners for Foreign Missions, CAP, NSCLC, Oncology, MRD, CLIA, Technology, Medical imaging, Pathology, Pharmacology, Biology

Research Triangle Park, NC, USA and Cambridge, UK, 13 December 2021 -- Inivata, a leader in liquid biopsy, today announced the appointment of David Eberhard MD, PhD as Chief Medical Officer (CMO). David will oversee the clinical and strategic development of Inivata’s liquid biopsy tests with a particular focus on its RaDaR™ assay for the detection of minimal residual disease (MRD).

Key Points: 
  • Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer
    Research Triangle Park, NC, USA and Cambridge, UK, 13 December 2021 -- Inivata, a leader in liquid biopsy, today announced the appointment of David Eberhard MD, PhD as Chief Medical Officer (CMO).
  • David holds a Bachelors degree in Biology from the University of South Dakota and a MD / PhD in Pharmacology from the University of Michigan.
  • David Eberhard, Chief Medical Officer at Inivata, commented: This is a truly exciting time to be joining Inivata, as it solidifies its position as a leader in the liquid biopsy space.
  • Inivata has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK.

New Data Presented at SABCS® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making

Retrieved on: 
木曜日, 12月 9, 2021
U.S. Securities and Exchange Commission, Risk, Neoplasm, Colon, Health, Exact sciences, National Cancer Institute, Security (finance), Genomic Health, Medicine, Radiation, Lymph, Woman, Tamoxifen, Death, Cancer, News, Patient, Breast cancer, Recurrence, Prostate cancer, Exact Sciences (company), Genomics, Down Home Sessions II, MAP, The New England Journal of Medicine, Oncotype (Denmark), National, NCI, NASDAQ, DCIS, Biology, Solution, Annual report, Breast, Dietary supplement, Medical imaging

MADISON, Wis., Dec. 9, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium® (SABCS®) supporting the clinical value of the Oncotype DX Breast Recurrence Score test. New analyses presented at the meeting include an oral presentation of updated data from the RxPONDER study led by the independent SWOG Cancer Research Network, and sponsored by the National Cancer Institute (NCI).

Key Points: 
  • Other data featured in Poster Sessions and Spotlight Poster Discussions at SABCS 2021 include the following:
    Poster #P1-08-28: Real world use of Oncotype DX testing in the management of breast cancer.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as risk of distant recurrence in invasive breast cancer.
  • Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Recurrence Score and Oncotype MAP are trademarks or registered trademarks of Genomic Health, Inc.

New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients

Retrieved on: 
火曜日, 11月 23, 2021
Patient, Oncotype (Denmark), Man, Risk assessment, News, Security (finance), Genomics, Prostate cancer, Cancer, Risk, Exact sciences, Time, Annual report, Death, Population, Diagnosis, MD, GPS, Cleveland, Genomic Health, Solution, U.S. Securities and Exchange Commission, Biopsy, AP, Urology, View, Health, Metastasis, TM, Exact Sciences (company), Cleveland Clinic, Multimedia, NASDAQ, Pathology, Medical imaging

In the study, analyses were performed on a sample of 428 patients, largely clinically low and intermediate risk (10% being clinically high risk), treated with radical prostatectomy (RP) between 1987 and 2004.

Key Points: 
  • In the study, analyses were performed on a sample of 428 patients, largely clinically low and intermediate risk (10% being clinically high risk), treated with radical prostatectomy (RP) between 1987 and 2004.
  • Adverse pathology was defined as either high-grade or high-stage disease (Gleason Grade 3 or above and/or non-organ confined disease, pT3 or higher).
  • Patients with no AP at surgery had a nearly zero risk of metastasis and death even at 20 years, while metastatic and death events rose immediately and sharply in the group of patients who had adverse pathology.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Genomic Prostate Score, and GPS are trademarks of Genomic Health, Inc..

Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs

Retrieved on: 
木曜日, 11月 4, 2021
Woman, Pregnancy, 2020 Marche regional election, Learning, Efficiency, U.S. Securities and Exchange Commission, Trustee, Sumathi Best Television Current Reporting Award, Stanford University, Syngenic, COVID-19, Intellectual disability, Health, Longevity, Death, Blood, Security (finance), Private Securities Litigation Reform Act, Blue Cross Blue Shield Association, Sera, Birth, Risk, Company, Education, Physician, Corizon, Harvard University, Hearing loss, Express Scripts, Harvard Board of Overseers, Premature, Protein, CEO, Overseer, Woody Myers, Seizure, Form, Preterm birth, Technology, Wellness, CPT, Health equity, Patient, NASDAQ, FDA, SALT, Health care, Cerebral palsy, Genomic Health, Board, Healthcare disparity in Massachusetts, Prospectus, Birth control, Management

SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Woodrow Myers, M.D., M.B.A.,joins Sera as an advisor focusing on public and political affairs.

Key Points: 
  • SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Woodrow Myers, M.D., M.B.A.,joins Sera as an advisor focusing on public and political affairs.
  • "We are honored to have Dr. Myers join the Sera Prognostics team, bringing his extensive experienceand leadership in addressing health equity and disparities," said Gregory C. Critchfield, M.D., M.S., Chairman, and CEO of Sera Prognostics.
  • Dr. Myers is on the boards of Personalis, Inc., Freespira Inc., and the Public Health Policy Committee of eHealth Inc.
  • Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc in the U.S. and/or other countries.